Ruthenium anticancer compounds: Challenges and expectations

被引:216
作者
Bratsos, Ioannis
Jedner, Stephanie
Gianferrara, Teresa
Alessio, Enzo
机构
[1] Univ Trieste, Dipartimento Sci Chim, I-34127 Trieste, Italy
[2] Univ Trieste, Dipartimento Sci Farmaceut, I-34127 Trieste, Italy
关键词
anticancer; antimetastatic; dimethylsulfoxide; medicinal inorganic; chemistry ruthenium;
D O I
10.2533/chimia.2007.692
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imiclazole) and [IndH] trans-[RuCl4(Ind)(2)] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms.
引用
收藏
页码:692 / 697
页数:6
相关论文
共 35 条
[11]   Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: A new strategy that might lead to improved activity [J].
Bratsos, Ioannis ;
Serli, Barbara ;
Zangrando, Ennio ;
Katsaros, Nikos ;
Alessio, Enzo .
INORGANIC CHEMISTRY, 2007, 46 (03) :975-992
[12]   Non-platinum chemotherapeutic metallopharmaceuticals [J].
Clarke, MJ ;
Zhu, FC ;
Frasca, DR .
CHEMICAL REVIEWS, 1999, 99 (09) :2511-2533
[13]   Ruthenium metallopharmaceuticals (vol 232, pg 69, 2002) [J].
Clarke, MJ .
COORDINATION CHEMISTRY REVIEWS, 2003, 236 (1-2) :207-+
[14]   Ruthenium metallopharmaceuticals [J].
Clarke, MJ .
COORDINATION CHEMISTRY REVIEWS, 2002, 232 (1-2) :69-93
[15]   Metal-based antitumour drugs in the post genomic era [J].
Dyson, PJ ;
Sava, G .
DALTON TRANSACTIONS, 2006, (16) :1929-1933
[16]   Clinical perspectives on platinum resistance [J].
Giaccone, G .
DRUGS, 2000, 59 (Suppl 4) :9-17
[17]   Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole):: Aquation, redox properties, protein binding, and antiproliferative activity [J].
Groessl, Michael ;
Reisner, Erwin ;
Hartinger, Christian G. ;
Eichinger, Rene ;
Semenova, Olga ;
Timerbaev, Andrei R. ;
Jakupec, Michael A. ;
Arion, Vladimir B. ;
Keppler, Bernhard K. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (09) :2185-2193
[18]  
Guo ZJ, 1999, ANGEW CHEM INT EDIT, V38, P1513
[19]   From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) [J].
Hartinger, Christian G. ;
Zorbas-Seifried, Stefanie ;
Jakupec, Michael A. ;
Kynast, Bernd ;
Zorbas, Haralabos ;
Keppler, Bernhard K. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2006, 100 (5-6) :891-904
[20]   Imidazole release from the antitumor-active ruthenium complex imidazolium trans-tetrachlorobis (imidazole) ruthenate(III) by biologically occurring nucleophiles [J].
Hartmann, M ;
Lipponer, KG ;
Keppler, BK .
INORGANICA CHIMICA ACTA, 1998, 267 (01) :137-141